Investors should be cautious on the potential for Gilead’s drug Remdesivir, analysts says

Remdesivir was one of the first medicines identified as a contender to treat Covid-19 given it showed promise in the past in treating SARS and MERS.
International: Top News And Analysis

Leave a Reply

Your email address will not be published. Required fields are marked *